Clinical Research Directory

Inclusion Criteria: * Women aged ≥18 years. * Undergoing scheduled or unscheduled cesarean delivery during the current admission, with or without concomitant salpingectomy. * Planned delivery under neuraxial anesthesia (spinal, epidural, or combined spinal-epidural). * Planned Pfannenstiel skin incision. * Able to provide informed consent in English or Spanish. * Willing and able to complete required remote follow-up assessments through postoperative day 14 (POD14). Exclusion Criteria: * Planned provision of breast milk to the neonate during the period of suzetrigine exposure (while the study drug is being taken and for 96 hours after last dose), due to the absence of human lactation safety data for suzetrigine.\* * Known allergy, hypersensitivity, or contraindication to suzetrigine or any component of its formulation. * Chronic opioid use, defined as daily opioid use for more than 7 consecutive days in the month prior to delivery, or current treatment for opioid use disorder. * Significant hepatic disease, defined as AST or ALT \>3 times the upper limit of normal or Child-Pugh class B or C. * Severe renal impairment, defined as estimated glomerular filtration rate (eGFR) \<15 mL/min. * Concurrent use of medications known to significantly alter suzetrigine metabolism, including strong CYP3A inhibitors or inducers, such as: * ketoconazole * ritonavir * carbamazepine * rifampin * St. John's wort (or other agents deemed clinically significant CYP3A modulators by the study investigator team) * Planned cesarean delivery under general anesthesia without neuraxial anesthesia. * Planned non-Pfannenstiel skin incision (e.g., vertical midline incision). * Participation in another interventional pain-management clinical trial during the current hospitalization. * Additional operative procedures (excluding salpingectomy) performed at the time of cesarean delivery (e.g., hysterectomy, hernia repair). * Inability to provide informed consent or to complete required study procedures and follow-up. * Receipt of opioid or sedating medications prior to completion of the informed consent process. * Feeding decisions are made independently of study participation. The study does not require participants to alter infant feeding plans; eligibility is determined solely by whether breast milk will be provided to the neonate during the period of study drug exposure (while the study drug is being taken and for 96 hours after last dose). Participants who plan to breastfeed but independently elect not to provide breast milk to the neonate during the period of suzetrigine exposure are eligible.